Bluebird bio has set wholesale acquisition cost of $2.8 million for the gene therapy beti-cel, now with the brand name Zynteglo, and is offering an outcomes-based contract with an 80% risk sharing. https://t.co/OjLt84LuJc

Shabbir J. Imber Safdar, executive director, Partnership for Safe Medicines, talks about efforts to address counterfeit drugs in the U.S. supply chain. https://t.co/C6VJfcZwKo

Those who spoke at a recent webinar discussed the prescription drug elements of the Inflation Reduction Act, which recently passed in the House, and the impact it will have on Medicare and its beneficiaries. https://t.co/nKpK7yqNgx

The PBM industry is facing increased scrutiny over policies and practices, but that could lead to unintended consequences. https://t.co/rC6NPF8LaE

CivicaScript is offering to pharmacies abiraterone 250 mg for $160 for a month’s supply. https://t.co/eKRBdHnVPk

This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype. Its approval comes four months ahead of its PDUFA action date. https://t.co/ofKQ5ZzPbb

The FDA has requested Acadia conduct an additional trial of Nuplazid to support an indication in patients with Alzheimer’s disease. https://t.co/0vPIsLNEcv

Fresenius Kabi expects to receive FDA approval for its tocilizumab biosimilar in 2023 and is seeking approval for its tocilizumab biosimilar in both intravenous and subcutaneous routes of administration. https://t.co/Q2oDpHLDJH

Coherus’ Cimerli has been approved to be interchangeable for all five indications, including age-related macular degeneration and diabetic retinopathy. It will be available in early October 2022. https://t.co/vSLEJo7CQW

Optum has teamed up with Sanofi to provide savings cards for six insulins through the Optum Store. https://t.co/UPOVq7ynDO

More than half of adults are unlikely to use a prescription drug that has experienced a recall. In an interview, Kelly Stanton, director of quality at Qualio, talks about the impact of prescription drug recalls. https://t.co/u8ONOWhj8f

If approved, Sandoz’ natalizumab would be the first biosimilar of Tysabri to treat patients with multiple sclerosis. https://t.co/hcqgylLZvx

Many of the more than 60 products added to the Express Scripts preferred drug list include prior authorization and other utilization management tools. https://t.co/9WDVkjSkE6

David Lassen, Pharm.D., chief clinical officer at Prime, discusses a pilot program that used a predictive model to identify patients at high risk of overusing opioids. https://t.co/saJFud7DWQ

The AIDS Healthcare Foundation claims that direct and indirect remuneration fees and other clawback programs amount to a breach of contract. https://t.co/4QaT7wdcFm

Navitus senior vice president and chief pharmacy officer Brent Eberle talks about how partnering with CivicaScript fits into its cost-plus model. https://t.co/FDvzF7mfOn

UnitedHealthcare will now offer some insulins, as well as some drugs used in emergency care, at $0 copay for eligible patients. https://t.co/g86oT9pjKU

Investigators suggest that policies that improve price transparency and increase competition for generic drugs could prevent patients and Medicare from overpaying on generic drugs. https://t.co/GD5cxesQm6

Drugs approved with an FDA breakthrough designation can provide value that offsets their higher costs, finds study conducted by Tufts Center for the Evaluation of Value and Risk in Health. https://t.co/6NpVf4oSMX

Biosimilars launch with a wholesale acquisition cost (WAC) that is up to 37% less than the reference products’ WAC. Additionally, average sales prices are declining for both reference products and biosimilars. https://t.co/RYkaABLanY